Bio-Rad Laboratories, Inc. (BIO) Stock: Price, Forecast & Analyst Target
Bio-Rad Laboratories, Inc. (BIO) — MoonshotScore 40/100 (Weak band), calculated Oct 4, 2026. Price $369.14 (+3.82%), as of the Oct 2, 2026 trading session; market cap $9.87B. Expected results Oct 29, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Bio-Rad Laboratories, Inc. · BIO · NYSE · Healthcare · Medical - Devices
Research dated 2026-09-13: Bio-Rad sells research reagents, laboratory instruments, diagnostic test systems, quality controls and related software to scientific and clinical laboratories; it is not simply a medical-device manufacturer. The case now rests on whether improving operating performance can persist while management still expects subdued demand across Life Science and Clinical Diagnostics.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Bio-Rad Laboratories (BIO)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and a strong balance sheet — and it’s docked well below the pillars; verify the gap before trusting the setup. Business Quality: Solid; Financial Safety: Sound; Valuation: Fair; Growth Durability: Flat; Momentum: Surging.
- quarterly revenue $651M (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 5 of 8
- expected results Oct 29, 2026
Helping: business quality, balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 40 | Weak | |
| 40 | Weak | |
| 40 | Weak | |
| 40 | Weak | |
| 40 | Weak | |
| 40 | Weak |
The score was 40 in the stored Oct 3, 2026 snapshot and remains 40 in the current publication computed Oct 4, 2026 (0).
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $369.14 | |
| Change on the day | +3.82% | |
| 52-week range | $236.73–$396.23 | |
| Market capitalisation | $9.87B | |
| Price / earnings (trailing) | 44.31 | |
| Shares traded on the day | 223.6K | |
| Beta (volatility vs the S&P 500) | 1.07 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Bio-Rad Laboratories (BIO): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the BIO film — every key number, told as a short cinematic story
~2 min · open the film
What is Bio-Rad Laboratories (BIO), and what does it report?
Short answer · as of
Life Science serves academic, government, biotechnology, pharmaceutical and food-testing customers with tools used in research, biopharmaceutical production and analytical workflows.
Research dated 2026-09-13.
Life Science serves academic, government, biotechnology, pharmaceutical and food-testing customers with tools used in research, biopharmaceutical production and analytical workflows. Clinical Diagnostics supplies hospital, reference, newborn-screening, physician-office and transfusion laboratories with test systems, reagents, informatics and quality controls.
Clinical Diagnostics contributes more revenue than Life Science, so reported sales measure a blend of research spending and routine clinical-laboratory demand. That mix makes Bio-Rad different from a pure equipment vendor: consumables, instruments and software all sit inside the reported business.
What do the latest results show for Bio-Rad Laboratories (BIO)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $651M.
Research dated 2026-09-13.
Revenue rebounded from the preceding period and returned close to its prior comparable level. Gross profit increased, operating profit rose sharply, and reported revenue and earnings exceeded market estimates in the latest release.
Management nevertheless reaffirmed an outlook ranging from contraction to only slight growth, with pressure contemplated in each operating segment. A recent filing also identifies costs associated with exit or disposal activities, making execution around those actions relevant to the operating improvement.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
| Sep 30, 2025 | Not available | Not available | Not available | Not available |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $651M | $371M | $13.85 (diluted) |
| Q1 FY2026 | $592M | -$527M | -$19.55 (diluted) |
| Q4 FY2025 | $693M | $720M | $26.65 (diluted) |
| Q3 FY2025 | $653M | -$342M | -$12.70 (diluted) |
What are the financial strengths and risks for Bio-Rad Laboratories (BIO)?
Short answer
Cash and short-term investments were $0.00 at the Jun 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
Bio-Rad's financial flexibility is substantial: cash and short-term investments exceed debt, while the broader pool including long-term investments exceeds total liabilities. Cash and short-term holdings have remained broadly stable across the reported window, and operating cash flow has stayed positive after capital spending.
The principal analytical risk is earnings quality rather than immediate liquidity. Operating profit remained positive while net results swung between large gains and losses, so headline net income can diverge sharply from the performance of the laboratory-products business. The trailing valuation therefore demands more than balance-sheet strength; it requires durable operating returns that are currently modest relative to equity and assets.
What should you watch next at Bio-Rad Laboratories (BIO)?
Short answer · as of
The next earnings report is expected on Oct 29, 2026.
Research dated 2026-09-13.
Watch whether revenue holds near the latest level while operating profit preserves its recent improvement. Segment performance matters: Life Science must contain the decline embedded in management's outlook, while Clinical Diagnostics needs to remain the steadier revenue base.
Cash conversion should corroborate any earnings progress through operating cash flow after capital spending. The scheduled earnings release also provides a direct test of management's reaffirmed margin framework and of analyst expectations for gradual revenue and earnings expansion beyond the current year.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Bio-Rad Laboratories compare with its peers?
Short answer
Bio-Rad Laboratories's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Bio-Rad combines research tools and clinical diagnostics under the same company, whereas many comparable businesses lean primarily toward laboratory research, diagnostic testing or medical equipment. Its larger Clinical Diagnostics operation supplies a stabilizing source of laboratory demand, while Life Science adds exposure to research budgets, biotechnology activity, biopharmaceutical production and food testing.
Another distinguishing feature is the investment-heavy balance sheet alongside comparatively modest operating returns. That combination can make reported net income and conventional earnings valuation less representative of the underlying operating business than revenue, operating profit and cash generation.
| Company | Price | Market value | Score |
|---|---|---|---|
| $75.60 Oct 2, 2026 | $10.2B | 96 5-pillar Oct 4, 2026 | |
| $317.55 Oct 2, 2026 | $12.5B | 95 5-pillar Oct 4, 2026 | |
| $75.07 Oct 2, 2026 | $4.12B | 88 5-pillar Oct 4, 2026 | |
| $26.42 Oct 2, 2026 | $11.1B | 87 5-pillar Oct 4, 2026 | |
| $208.54 Oct 2, 2026 | $20.3B | 87 5-pillar Oct 4, 2026 | |
| $143.74 Oct 2, 2026 | $10.3B | 83 5-pillar Oct 4, 2026 | |
| $131.69 Oct 2, 2026 | $9.12B | 83 5-pillar Oct 4, 2026 | |
| $88.29 Oct 2, 2026 | $17.1B | 80 5-pillar Oct 4, 2026 | |
| $178.69 Oct 2, 2026 | $11.5B | 76 5-pillar Oct 4, 2026 | |
| $23.92 Oct 2, 2026 | $23.4B | 74 5-pillar Oct 4, 2026 | |
| $126.45 Oct 2, 2026 | $4.29B | 71 5-pillar Oct 4, 2026 | |
| $63.24 Oct 2, 2026 | $9.63B | 59 5-pillar Oct 4, 2026 | |
| Bio-Rad Laboratories (BIO) — this page | $369.14 | $9.87B | 40 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $310.00 – $390.00
- Consensus target
- $350.00
- Median target
- $350.00
Consensus record · Captured .
Measured against a quoted price of $369.14 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 6, 2026
- Transactions
- 94
- Identified insiders
- 13
- Purchases
- 0
- Sales
- 1
- Other transactions
- 93
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
What has been published about Bio-Rad Laboratories (BIO)?
BIO Healthcare Stock FAQ
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
Why does Bio-Rad sell more than medical devices?
Bio-Rad supplies reagents, diagnostic kits, quality controls, laboratory instruments and informatics as well as equipment. Demand therefore comes from recurring laboratory workflows and research activity, not solely from purchases of capital devices.
Why can Bio-Rad's net income diverge from operating profit?
Operating profit remained positive across the reported periods while net results moved between substantial gains and losses. Revenue, operating profit and cash flow consequently provide a cleaner view of laboratory-product performance than net income alone.
Is Clinical Diagnostics larger than Bio-Rad's Life Science business?
Clinical Diagnostics contributes more revenue than Life Science. Its hospital, reference, screening and transfusion laboratory customers give Bio-Rad a demand base distinct from the academic, biotechnology and pharmaceutical customers served by Life Science.
What would confirm Bio-Rad's reaffirmed margin framework?
Confirmation would require operating profitability to hold above its trailing level while revenue remains within management's subdued range. Continued cash generation after capital spending would strengthen that evidence.
What is the BIO stock price today?
The last price recorded on this page for Bio-Rad Laboratories, Inc. (BIO) is $369.14, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the BIO price target?
The analyst consensus price target for Bio-Rad Laboratories, Inc. (BIO) is $350.00 (range $310.00 to $390.00, median $350.00), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
When are BIO's next earnings?
The next earnings date listed on this page for Bio-Rad Laboratories, Inc. (BIO) is Oct 29, 2026. Companies sometimes move report dates, so the company's own announcement is the final word on timing.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (26 figures)
The 26 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | Hercules, CA | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "1000 Alfred Nobel Drive, Hercules, CA, 94547, US". |
FMP — 21 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $369.14 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T20:54:54.614Z. | |
px.change | Change on the day | +3.82% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalization | $9.87B | FMP | Financial Modeling Prep (FMP) quote — Provider market cap uses the share class it prices; a company with more than one class may show a larger total elsewhere. Market cap record date: 2026-10-04. Source capture time was not supplied. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$13.57 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $651M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $236.73–$396.23 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 44.31 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 223.6K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 1.07 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Norman D. Schwartz | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 7,450 | FMP | Financial Modeling Prep (FMP) company profile | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY1970 through FY2025: FY1970 revenue $0.00, net result $0.00; FY2022 revenue $0.00, net result $0.00; FY2023 revenue $0.00, net result $0.00; FY2024 revenue $0.00, net result $0.00; FY2025 revenue $0.00, net result $0.00 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.gross_margin | Gross margin (trailing twelve months) | 52.0% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. The market-value ratio is undefined when the reported amount is zero. | |
fin.total_debt | Total debt | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 1.38× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
earn.pt_range | Analyst price target, low to high | $310.00 – $390.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $350.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $350.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 94 transactions · 0 purchases, 1 sales, 93 other transactions · 13 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 6, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Oct 29, 2026 | UNRECORDED | Stored earnings-calendar observation — Captured 2026-09-14 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 5 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-04 |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 40 of 100 · Weak · pillars 76 / 75 / 65 / 56 / 87 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 40 (stored snapshot Oct 3, 2026) → 40 (current publication computed Oct 4, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Sector / industry (provider taxonomy) | Healthcare / Medical - Devices The company's SEC filings classify it under SIC 3826 — Laboratory Analytical Instruments. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Life Science: $1.02B; Clinical Diagnostics: $1.56B | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Management outlook — dated call excerpts | Captured record · 4 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-08-04 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-04 | FMP | Financial Modeling Prep (FMP) earnings |
| Recent SEC filings |
| 2026-08-04 | OFFICIAL | SEC EDGAR filer submissions |
| Most recent periodic reports | Annual: Document: https://www.sec.gov/Archives/edgar/data/12208/000001220826000010/bio-20251231.htm, Filed: 2026-02-13, Period end: 2025-12-31; Quarterly: Document: https://www.sec.gov/Archives/edgar/data/12208/000001220826000048/bio-20260630.htm, Filed: 2026-08-04, Period end: 2026-06-30 | 2026-08-04 | OFFICIAL | SEC EDGAR filer submissions |
| Cash, investments and debt | Total debt: $1.20B; Liquidity basis: cash and short-term investments; Total liabilities: $3.08B; Cash and short-term investments: $1.62B; Cash and investments: $7.34B; Long-term investments: $5.72B; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $7.34B; Cash and short-term investments: $1.62B; Long-term investments: $5.72B; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash decline over the reported window | To: 2026-06-30; From: 2024-09-30; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $1.62B; Decline: $4.00M; Opening balance: $1.62B; Average change per period: $600,000 Change in cash, cash equivalents and short-term investments between the 2024-09-30 and 2026-06-30 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-06-30 | COMPUTED | Computed from reported balances |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Trailing twelve-month ratio set | Quick ratio: 2.33; Current ratio: 3.14; Debt to equity: 0.17; Net margin: 8.6%; Gross margin: 51.9%; Operating margin: 9.1%; Return on assets: 2.2%; Return on equity: 3.2% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Distress and quality screens | Altman Z-score: 3.65; Piotroski F-score: 7 Altman Z below 1.8 is the conventional distress zone. The screen is built for manufacturers and industrials; for banks, insurers and property companies it is not a meaningful reading. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) financial scores |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: $414.80M; Total debt: $1.20B; Cash and investments: $1.62B Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Next earnings report | Date: 2026-10-29; EPS estimate: $2.23 per share; Revenue estimate: $650.64M The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
Data provided for informational purposes only.